Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1131

Shown on this page

Current sort

Live official records

Conditions: Dementia Family Caregiver, Dementia, Medication Adherence
Interventions: Medication Collaboration Intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Solid Tumors Harboring MET Amplification
Interventions: Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Interventions: AI-Enabled Identification (EchoNet-Liver); Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Pleasanton, California + 2 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 36
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 28 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 54
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more

Conditions: Breast Cancer
Interventions: Core Intervention, E-Coach, Buddy, General Mindfulness Training, MVPA-Specific Mindfulness Training; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions: GORE® VIAFORT Vascular Stent; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 24
States / cities: Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more

Conditions: Myeloproliferative Neoplasms
Interventions: INCB160058, Standard disease-directed therapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • Tampa, Florida + 8 more

Conditions: Cancer
Interventions: Internet-based pain coping skills program; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 149
States / cities: Fort Smith, Arkansas • Antioch, California • Dublin, California + 118 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Navitoclax, Pharmacological Study, Trametinib; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 49
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more

Conditions: Healthy Adult, Flushing
Interventions: Genetic Test Results Return, Alcohol Flushing Education; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Adenocarcinoma
Interventions: enzalutamide; Drug
Lead sponsor: Alessa Therapeutics Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Fresno, California • San Francisco, California • Chicago, Illinois + 7 more

About this Northwestern Medicine institution page

What this page lists: ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Northwestern Medicine

Filter and sort this campus

Live official records

Medication Collaboration Feasibility Study

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

An Internet-based Program to Help Cancer Survivors Manage Pain

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

ALDH2 Genetic Testing in East Asian Community

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

About this Northwestern Medicine institution page